Management of Unresectable Localized Pelvic Bone Sarcomas: Current Practice and Future Perspectives

• Published in: Cancers Vol. 14; no. 10; p. 2546
• Main Authors: Soares do Brito, Joaquim, Esperança-Martins, Miguel, Abrunhosa-Branquinho, André, Melo-Alvim, Cecilia, Lopes-Brás, Raquel, Janeiro, João, Lopez-Presa, Dolores, Fernandes, Isabel, Portela, José, Costa, Luis
• Format: Journal Article
• Language: English
• Published: Switzerland MDPI AG 22-05-2022; MDPI
• Subjects: Atoms & subatomic particles; Blood vessels; Bone cancer; Bone tumors; Bones; Ewings sarcoma; Mesenchyme; Metastasis; Patients; Pelvis; Radiation therapy; Review; Sarcoma; Surgery; Tumors; treatment option; management; unresectable bone sarcoma; pelvic bone sarcoma
• ISSN: 2072-6694; 2072-6694
• DOI: 10.3390/cancers14102546

Bone sarcomas (BS) are rare mesenchymal tumors usually located in the extremities and pelvis. While surgical resection is the cornerstone of curative treatment, some locally advanced tumors are deemed unresectable and hence not suitable for curative intent. This is often true for pelvic sarcoma due to anatomic complexity and proximity to vital structures, making treatment options for these tumors generally limited and not unanimous, with decisions being made on an individual basis after multidisciplinary discussion. Several studies have been published in recent years focusing on innovative treatment options for patients with locally advanced sarcoma not amenable to local surgery. The present article reviews the evidence regarding the treatment of patients with locally advanced and unresectable pelvic BS, with the goal of providing an overview of treatment options for the main BS histologic subtypes involving this anatomic area and exploring future therapeutic perspectives. The management of unresectable localized pelvic BS represents a major challenge and is hampered by the lack of comprehensive and standardized guidelines. As such, the optimal treatment needs to be individually tailored, weighing a panoply of patient- and tumor-related factors. Despite the bright prospects raised by novel therapeutic approaches, the role of each treatment option in the therapeutic armamentarium of these patients requires solid clinical evidence before becoming fully established.